EcoDrugPlus

5-Hydroxytryptamine Receptor 1a-Beta

Ensembl ID : ENSAPOG00000018648
Gene Symbol: LOC110957192
3 Cross references
137 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSAPOG00000009051
Gene Symbol: HTR1B
4 Cross references
178 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSAPOG00000013604
Gene Symbol: HTR1B
1 Cross references
180 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSAPOG00000016833
Gene Symbol: HTR1E
2 Cross references
147 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSAPOG00000004658
Gene Symbol: HTR1F
4 Cross references
140 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSAPOG00000013913
Gene Symbol: HTR2A
2 Cross references
212 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSAPOG00000011019
Gene Symbol: HTR2A
1 Cross references
212 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSAPOG00000013881
Gene Symbol: HTR2A
2 Cross references
212 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a-Like

Ensembl ID : ENSAPOG00000021802
Gene Symbol: LOC110957720
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSAPOG00000011638
Gene Symbol: HTR2B
3 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSAPOG00000000476
Gene Symbol: HTR3A
3 Cross references
205 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSAPOG00000017718
Gene Symbol: HTR3B
3 Cross references
175 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).